本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Pharvaris N.V.

15.09
+0.59004.07%
盘后15.090.00000.00%16:05 EDT
成交量:3.31万
成交额:50.12万
市值:8.22亿
市盈率:-5.87
高:16.00
开:15.17
低:14.56
收:14.50
数据加载中...

公司资料

公司名字:
Pharvaris N.V.
交易所:
NASDAQ
成立时间:
2015
员工人数:
108
公司地址:
Emmy Noetherweg 2,Leiden,Zuid-Holland,Netherlands
邮编:
2333 BK
传真:
- -
简介:
Pharvaris N.V.于2015年9月30日注册在荷兰成立。他们是一家临床阶段的生物制药公司,致力于针对尚未满足需求的罕见疾病的创新疗法的开发和商业化,最初的重点是血管性水肿和其他缓激肽介导的疾病。他们的第一个分子PHA121是新型的小分子缓激肽B2受体拮抗剂,可用于治疗遗传性血管性水肿或HAE。

董事

名称
职位
Berndt Modig
Chief Executive Officer and Executive Director
Anne Marie de Jonge Schuermans
Non-Executive Director
David Meeker
Non-Executive Director
Elisabeth Bjork
Non-Executive Director
Hans Schikan
Non-Executive Director
Robert Glassman
Non-Executive Director
Viviane Monges
Non-Executive Director

股东

名称
职位
Berndt Modig
Chief Executive Officer and Executive Director
Jochen Knolle
Chief Scientific Officer and Chief Operating Officer
Anna Nijdam
Head of Finance and Principal Accounting Officer
Anne Lesage
Chief Early Development Officer
Annick Deschoolmeester
Chief Human Resources Officer
Joan Schmidt
Chief Legal Officer
Morgan Conn
Chief Business Officer
Peng Lu
Chief Medical Officer
Wim Souverijns
Chief Community Engagement and Commercial Officer